Tags

Type your tag names separated by a space and hit enter

[A cohort study on the association between fasting plasma glucose level over 5.3 mmol/L and risks of abnormal glucose metabolism and cardiovascular diseases in the elderly].
Zhonghua Nei Ke Za Zhi. 2016 May 01; 55(5):340-4.ZN

Abstract

OBJECTIVE

The aim of the study was to evaluate the association of fasting plasma glucose (FPG) level over 5.3 mmol/L to the development of abnormal glucose metabolism and cardiovascular diseases (CVD).

METHODS

This was a retrospective cohort study with 1 064 non-diabetic subjects(980 males; 84 females) aged 60 or over, who carried out annual health check-up in Chinese PLA General Hospital from May, 1996 to May, 2015. Based on the average FPG level of 3 years before enrollment, the subjects were divided into four groups: <5.3 mmol/L, 5.3-<5.6 mmol/L, 5.6-<6.1 mmol/L and 6.1-<7.0 mmol/L. Glucose metabolic changes, complications and mortality were follow-up until May, 2015.

RESULTS

(1)The initial 3-year average FPG levels were (4.9±0.4) mmol/L in the total 1 064 subjects. Among them, 126 subjects developed diabetes mellitus (DM) and 144 subjects developed impaired glucose regulation (IGR) during the follow-up visits. The proportions of IGR and diabetes increased with the FPG levels (P<0.05). The risk for developing IGR was significantly higher in subjects with FPG≥5.3 mmol/L than in those with FPG <5.3 mmol/L (RR=3.08, 95%CI 2.02-4.81, P<0.01). The risk for incident DM was markedly increased in subjects with FPG ≥ 5.6 mmol/L than in those with FPG <5.6 mmol/L (RR=6.73, 95%CI 3.90-11.52, P<0.01); (2)The risk for CVD was eight folds higher in subjects with FPG ≥5.3 mmol/L than in subjects with FPG <5.3 mmol/L (RR=8.42, 95%CI 5.11-13.82, P<0.05); (3)Survival analysis showed that the risk of death was 1.47 times higher in subjects with FPG ≥5.3 mmol/L than in subjects with FPG <5.3 mmol/L after years of followed-up (RR=1.47, 95%CI 1.09-1.98, P=0.0127).

CONCLUSION

The risks for IGR, CVD and mortality are higher in the elderly with FPG≥5.3 mmol/L, which highlights the importance for the disease prevention in elder people with FPG 5.3 mmol/L or more.

Authors+Show Affiliations

Department of Geriatric Endocrinology, Chinese PLA General Hospital, Beijing 100853, China.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

chi

PubMed ID

27143181

Citation

Zhao, M X., et al. "[A Cohort Study On the Association Between Fasting Plasma Glucose Level Over 5.3 mmol/L and Risks of Abnormal Glucose Metabolism and Cardiovascular Diseases in the Elderly]." Zhonghua Nei Ke Za Zhi, vol. 55, no. 5, 2016, pp. 340-4.
Zhao MX, Kan FF, Fang FS, et al. [A cohort study on the association between fasting plasma glucose level over 5.3 mmol/L and risks of abnormal glucose metabolism and cardiovascular diseases in the elderly]. Zhonghua Nei Ke Za Zhi. 2016;55(5):340-4.
Zhao, M. X., Kan, F. F., Fang, F. S., & Tian, H. (2016). [A cohort study on the association between fasting plasma glucose level over 5.3 mmol/L and risks of abnormal glucose metabolism and cardiovascular diseases in the elderly]. Zhonghua Nei Ke Za Zhi, 55(5), 340-4. https://doi.org/10.3760/cma.j.issn.0578-1426.2016.05.002
Zhao MX, et al. [A Cohort Study On the Association Between Fasting Plasma Glucose Level Over 5.3 mmol/L and Risks of Abnormal Glucose Metabolism and Cardiovascular Diseases in the Elderly]. Zhonghua Nei Ke Za Zhi. 2016 May 1;55(5):340-4. PubMed PMID: 27143181.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [A cohort study on the association between fasting plasma glucose level over 5.3 mmol/L and risks of abnormal glucose metabolism and cardiovascular diseases in the elderly]. AU - Zhao,M X, AU - Kan,F F, AU - Fang,F S, AU - Tian,H, PY - 2016/5/5/entrez PY - 2016/5/5/pubmed PY - 2017/1/11/medline SP - 340 EP - 4 JF - Zhonghua nei ke za zhi JO - Zhonghua Nei Ke Za Zhi VL - 55 IS - 5 N2 - OBJECTIVE: The aim of the study was to evaluate the association of fasting plasma glucose (FPG) level over 5.3 mmol/L to the development of abnormal glucose metabolism and cardiovascular diseases (CVD). METHODS: This was a retrospective cohort study with 1 064 non-diabetic subjects(980 males; 84 females) aged 60 or over, who carried out annual health check-up in Chinese PLA General Hospital from May, 1996 to May, 2015. Based on the average FPG level of 3 years before enrollment, the subjects were divided into four groups: <5.3 mmol/L, 5.3-<5.6 mmol/L, 5.6-<6.1 mmol/L and 6.1-<7.0 mmol/L. Glucose metabolic changes, complications and mortality were follow-up until May, 2015. RESULTS: (1)The initial 3-year average FPG levels were (4.9±0.4) mmol/L in the total 1 064 subjects. Among them, 126 subjects developed diabetes mellitus (DM) and 144 subjects developed impaired glucose regulation (IGR) during the follow-up visits. The proportions of IGR and diabetes increased with the FPG levels (P<0.05). The risk for developing IGR was significantly higher in subjects with FPG≥5.3 mmol/L than in those with FPG <5.3 mmol/L (RR=3.08, 95%CI 2.02-4.81, P<0.01). The risk for incident DM was markedly increased in subjects with FPG ≥ 5.6 mmol/L than in those with FPG <5.6 mmol/L (RR=6.73, 95%CI 3.90-11.52, P<0.01); (2)The risk for CVD was eight folds higher in subjects with FPG ≥5.3 mmol/L than in subjects with FPG <5.3 mmol/L (RR=8.42, 95%CI 5.11-13.82, P<0.05); (3)Survival analysis showed that the risk of death was 1.47 times higher in subjects with FPG ≥5.3 mmol/L than in subjects with FPG <5.3 mmol/L after years of followed-up (RR=1.47, 95%CI 1.09-1.98, P=0.0127). CONCLUSION: The risks for IGR, CVD and mortality are higher in the elderly with FPG≥5.3 mmol/L, which highlights the importance for the disease prevention in elder people with FPG 5.3 mmol/L or more. SN - 0578-1426 UR - https://www.unboundmedicine.com/medline/citation/27143181/[A_cohort_study_on_the_association_between_fasting_plasma_glucose_level_over_5_3_mmol/L_and_risks_of_abnormal_glucose_metabolism_and_cardiovascular_diseases_in_the_elderly]_ L2 - http://journal.yiigle.com/LinkIn.do?linkin_type=pubmed&amp;issn=0578-1426&amp;year=2016&amp;vol=55&amp;issue=5&amp;fpage=340 DB - PRIME DP - Unbound Medicine ER -